Sanofi Presents Results of Amlitelimab (KY1005) in P-IIa Study for the Treatment of Moderate-To-Severe Atopic Dermatitis at EADV 2021

Shots:

• The P-IIa study evaluates amlitelimab (IV, low/high dose, q4w over 12wks.) vs PBO in 88 patients with mod. to sev. AD inadequately controlled with topical therapies
• The co-primary EPs include @16wks., improvement in avg. EASI from baseline (80%/70% vs 49%) in LD/HD, no difference in responses was observed in both doses & the overall rate of TEAEs (35%/17% vs 31%) respectively
• The 2EPs includes @16wks., (44%/ 37% vs 8%) patients with LD/HD achieved a score of 0 or 1 on vIGA scale & maintained response. In both doses, (59%/52% vs 25%) & (33%/30% vs 13%) patients achieved ≥75% & 90% skin improvement (EASI-75) & (EASI-790), improvement in mean percent CFB in SCORAD (60%/59% vs 37%) respectively

Click here to­ read full press release/ article | Ref: Sanofi | Image: Campaign India